Holderried, Tobias A. W.
de Vos, Luka
Bawden, Emma Grace
Vogt, Timo J.
Dietrich, Joern
Zarbl, Romina
Bootz, Friedrich
Kristiansen, Glen
Brossart, Peter
Landsberg, Jennifer
Dietrich, Dimo http://orcid.org/0000-0001-9794-7927
Article History
Received: 20 May 2019
Accepted: 23 September 2019
First Online: 20 November 2019
Consent for publication
: Not applicable.
: Dimo Dietrich owns patents and patent applications on biomarker technologies and methylation of immune checkpoint genes as predictive and prognostic biomarkers (DE 10 2016 005 947.8, DE 10 2015 009 187.5, DE 10 2017 125 780.2, PCT/EP2016/001237). The patents are licensed to Qiagen GmbH (Hilden, Germany). Dimo Dietrich is a consultant of Qiagen. The University Hospital Bonn (PI Dimo Dietrich) receives research funding from Qiagen. The other authors have declared that no conflict of interest exists.